Advances in cancer immunology have enabled the development of more sophisticated vaccine platforms targeting tumor-associated antigens (TAAs), such as carcinoembryonic antigen (CEA) and human chorionic gonadotropin β (hCGβ), and dendritic cell-based vaccines that present tumor antigens more effectively [18]. This evidence concerns the gene CEACAM5 and neoplasm.